Fathoming the Role of Semaglutide in Obesity Therapeutics

Clin Ther. 2023 Aug;45(8):804-805. doi: 10.1016/j.clinthera.2023.06.021. Epub 2023 Jul 11.

Authors

Melvin George¹, Karthik Balachandran², Juanna Jinson³

Affiliations

¹ Clinical Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamil Nadu, India. Electronic address: melvingeorge2003@gmail.com.
² Endocrinology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India.
³ Clinical Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamil Nadu, India.

PMID: 37442659
DOI: 10.1016/j.clinthera.2023.06.021

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptides* / therapeutic use
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use

Substances

semaglutide
Glucagon-Like Peptides
Hypoglycemic Agents